As we close this Advent series and the year, we want to take a step back from individual technologies, karyotyping, mycoplasma testing, rapid methods and look at the bigger picture with Laurent Claisse our CEO. With him, we want to understand where Clean Cells stands today, what is changing on the market, and how we intend to serve our clients and their patients in the years to come.
Over the past 25 years, Clean Cells has grown from a specialist in mycoplasma detection to a GMP-certified, FDA-inspected partner covering biosafety testing, cell and virus bank manufacturing, and secure storage for biologics and advanced therapies. With the inauguration of our 5,300 m² cGMP facility in Montaigu-Vendée, now one of the largest European platforms dedicated to biopharmaceutical quality control and cell bank production, we have significantly expanded our capacity and capabilities.
Buildings and instruments are impressive, but they are only tools, the real implication is to use this platform to answer the concrete challenges our clients face.
